Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China.
Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.
J Tradit Chin Med. 2020 Feb;40(1):94-102.
To investigate the mechanism underlying the effects of Shichangpu (Rhizoma Acori Tatarinowii) on attention deficit hyperactivity disorder (ADHD).
A network pharmacology approach integrating ingredients of Shichangpu (Rhizoma Acori Tatarinowii) and target with ADHD, network construction, molecular function interactions and pathway analysis was used.
This approach successfully helped to identify 7 active ingredients of CN, interacting with 21 key targets (ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, CHRM1, CHRM2, CHRM3, PTGS1, SLC6A2, SLC6A3, SLC6A4, DRD1, DRD5, HTR2A, ADRA1D, MAOB, GRIA2, HTR1A). The molecular function interactions among candidate targets mainly consisted of four groups: G-protein coupled amine receptor activity, catecholamine binding, monoamine transmembrane transporter activity and neurotransmitter receptor activity. Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis indicated that Shichangpu (Rhizoma Acori Tatarinowii)-regulated pathways were mainly classified into signal transduction and monoamine neurotransmitters.
Our investigation revealed that Shichangpu (Rhizoma Acori Tatarinowii) could improve the symptoms of ADHD by regulating neurotransmitter, in multiple types of compounds-target-pathway, which may be implicated in the major pathological processes of ADHD.
探讨石菖蒲治疗注意缺陷多动障碍(ADHD)的作用机制。
采用网络药理学方法,整合石菖蒲的成分与 ADHD 的靶点,构建网络,进行分子功能相互作用和通路分析。
该方法成功鉴定出石菖蒲的 7 种活性成分,与 21 个关键靶点(ADRA1A、ADRA1B、ADRA2A、ADRA2B、ADRA2C、ADRB1、ADRB2、CHRM1、CHRM2、CHRM3、PTGS1、SLC6A2、SLC6A3、SLC6A4、DRD1、DRD5、HTR2A、ADRA1D、MAOB、GRIA2、HTR1A)相互作用。候选靶点的分子功能相互作用主要包括四组:G 蛋白偶联胺受体活性、儿茶酚胺结合、单胺跨膜转运体活性和神经递质受体活性。京都基因与基因组百科全书通路富集分析表明,石菖蒲调节的通路主要分为信号转导和单胺神经递质。
本研究表明,石菖蒲通过调节神经递质改善 ADHD 症状,可能与 ADHD 的主要病理过程有关,涉及多种化合物-靶点-通路。